Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Free Cash Flow to The Firm (FCFF)

Bristol-Myers Squibb Co., FCFF calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net earnings (loss) attributable to BMS (8,948) 8,025 6,327 6,994 (9,015)
Noncontrolling interest 15 15 18 20 20
Net noncash charges 23,313 7,734 8,950 10,446 22,064
Changes in operating assets and liabilities 810 (1,914) (2,229) (1,253) 983
Net cash provided by operating activities 15,190 13,860 13,066 16,207 14,052
Interest payments, net of tax1 1,422 1,144 1,152 1,299 1,264
Capital expenditures (1,248) (1,209) (1,118) (973) (753)
Free cash flow to the firm (FCFF) 15,364 13,795 13,100 16,533 14,563

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Item Description The company
FCFF Free cash flow to the firm is the cash flow available to the Bristol-Myers Squibb Co. suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. Bristol-Myers Squibb Co. FCFF increased from 2022 to 2023 and from 2023 to 2024.

Interest Paid, Net of Tax

Bristol-Myers Squibb Co., interest paid, net of tax calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Effective Income Tax Rate (EITR)
EITR1 21.00% 4.70% 17.70% 13.40% 21.00%
Interest Paid, Net of Tax
Interest payments, before tax 1,800 1,200 1,400 1,500 1,600
Less: Interest payments, tax2 378 56 248 201 336
Interest payments, net of tax 1,422 1,144 1,152 1,299 1,264

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 See details »

2 2024 Calculation
Interest payments, tax = Interest payments × EITR
= 1,800 × 21.00% = 378


Enterprise Value to FCFF Ratio, Current

Bristol-Myers Squibb Co., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV) 162,611
Free cash flow to the firm (FCFF) 15,364
Valuation Ratio
EV/FCFF 10.58
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc. 21.52
Amgen Inc. 16.18
Danaher Corp. 28.55
Eli Lilly & Co. 191.73
Gilead Sciences Inc. 14.24
Johnson & Johnson 19.12
Merck & Co. Inc. 13.02
Pfizer Inc. 14.99
Regeneron Pharmaceuticals Inc. 16.88
Thermo Fisher Scientific Inc. 24.40
Vertex Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences 23.57
EV/FCFF, Industry
Health Care 23.26

Based on: 10-K (reporting date: 2024-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Bristol-Myers Squibb Co., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Enterprise value (EV)1 152,789 126,048 181,761 173,993 169,334
Free cash flow to the firm (FCFF)2 15,364 13,795 13,100 16,533 14,563
Valuation Ratio
EV/FCFF3 9.94 9.14 13.87 10.52 11.63
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc. 20.05 14.89 12.15 13.18 13.95
Amgen Inc. 15.35 22.22 16.01 15.82 14.51
Danaher Corp. 28.93 36.34 25.74 28.25 30.66
Eli Lilly & Co. 200.93 655.33 59.14 38.37 39.01
Gilead Sciences Inc. 14.50 13.41 13.58 8.42 13.60
Johnson & Johnson 18.16 19.30 23.80 21.25 20.75
Merck & Co. Inc. 13.24 37.84 19.09 23.27 34.12
Pfizer Inc. 15.33 32.24 9.15 8.40 21.74
Regeneron Pharmaceuticals Inc. 19.30 23.99 17.96 9.81 25.74
Thermo Fisher Scientific Inc. 26.13 28.85 31.61 33.14 26.14
Vertex Pharmaceuticals Inc. 29.45 16.68 22.47 16.00
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences 23.57 27.24 17.95 16.12 19.74
EV/FCFF, Industry
Health Care 22.99 24.06 17.76 17.08 18.03

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 See details »

2 See details »

3 2024 Calculation
EV/FCFF = EV ÷ FCFF
= 152,789 ÷ 15,364 = 9.94

4 Click competitor name to see calculations.

Valuation ratio Description The company
EV/FCFF Enterprise value to free cash flow to the firm is whole company valuation indicator. Bristol-Myers Squibb Co. EV/FCFF ratio decreased from 2022 to 2023 but then slightly increased from 2023 to 2024.